The Food and Drug Administration (FDA) has recently advanced two efforts aimed at improving the drug development process: an Expedited Investigational New Drug (IND) Pilot designed to move promising therapies into clinical testing more quickly, and a renewed emphasis on whether clinical data – particularly data generated outside the United States – meet Good Clinical Practice (GCP) standards and can be independently verified. Both reflect a sensible instinct to identify problems earlier rather than allow them to surface late in review. But neither is likely to be revolutionary in its outcome. 

The new Expedited IND Pilot – launched on September 15 – is the latest agency move to speed drug development. While billed as an information-gathering pilot program, it will likely prove an unsurprising “known-known”: Drug development moves more efficiently when sponsors and regulators identify problems early rather than waiting until a completed application lands on FDA’s desk. That would be useful, but it is not revolutionary. 

FDA’s IND pilot intends to shorten the path between identifying a promising drug candidate and beginning a first-in-human clinical trial. Under the program, the FDA will select between eight and 10 drug sponsor–qualified research institution (QRI) pairs, with applications due October 30. These pairs will work across nonclinical, clinical, and chemistry, manufacturing, and controls issues. Sponsors will then be able to submit discrete IND components during the pre-IND period for FDA review rather than waiting until the entire application is complete. The statutory 30-day IND review period remains in place once the final application is submitted. 

There is plenty to like about the concept. Earlier feedback can identify studies that actually need to be performed, distinguish potential clinical hold issues from improvements that would strengthen an application, and allow activities such as Institutional Review Board assessment and site preparation to proceed concurrently. The FDA has pursued the effort with some verve, describing the model as capable of fundamentally changing pre-IND development timelines.  

But the underlying regulatory strategy is familiar in FDA programs. The Fast Track pathway already provides more frequent communication and rolling review; Breakthrough Therapy designation adds intensive FDA guidance and organizational commitment; and programs such as Real-Time Oncology Review have demonstrated that earlier, iterative examination of evidence can compress regulatory timelines. The Expedited IND Pilot applies a similar philosophy further upstream and seeks to add QRIs as an intermediary layer between sponsors and the FDA. 

The scale of the experiment is therefore important to consider. As previously mentioned, this program is a pilot and will enroll very few sponsor-QRI pairs to begin. For perspective, Center for Drug Research and Evaluation received 1,960 new drug and non-biosimilar biologic INDs in 2025, including 1,210 commercial applications, and recorded activity on 15,124 INDs during the year. Those figures are not a direct denominator for pilot eligibility, but they illustrate the enormous difference between providing exceptional attention to several programs and making that same attention routine.  

This workload doesn’t stop at IND filings. In fiscal year 2024, sponsors submitted 4,936 formal Prescription Drug User Fee Amendments (PDUFA) meeting requests across Types A, B, B(EOP), C, D, and INitial Targeted Engagement for Regulatory Advice on CBER/CDER ProducTs (INTERACT). In total, the FDA recorded 12,770 actions associated with PDUFA procedural and processing commitments that year. The agency met many of its performance targets, but those numbers underscore the opportunity cost of turning intensive regulator-sponsor engagement into the default model. Reviewer hours devoted to one program cannot simultaneously be devoted to another.  

The pilot’s most valuable result will likely not be proving that an interactive, close-touch approach works (although it probably will). The more important question is which pieces of that approach can be smoothed so they no longer require extraordinary FDA attention. The QRI experiment could be interesting on that front. The FDA envisions these organizations as substantive scientific partners capable of determining whether submissions contain appropriate, phase-specific evidence before those materials reach the agency. If the pilot eventually produces reliable standards for accrediting or evaluating QRIs in line with FDA statutory requirements, some expertise now supplied through repeated agency interactions could be embedded earlier in development. 

The separate announcement on GCP standards addresses a more nuanced issue. The FDA said it will increase scrutiny of clinical evidence generated at foreign sites, particularly where the agency cannot inspect facilities, assess compliance with Good Clinical Practice, or independently validate the underlying data. Concern may be legitimate: The FDA has previously identified cases involving fabricated participants, falsified laboratory results, concealed adverse events, and restrictions on foreign inspections. Sponsors should not be able to build applications around evidence that regulators cannot adequately verify or that fail to meet established GCP standards. 

But the FDA should be careful that an admonitory message about data integrity does not further the denigration of clinical research conducted outside the United States. Modern drug development depends heavily on international trials, and sponsors use them for reasons ranging from faster patient recruitment to disease prevalence and scientific expertise. FDA should target actual evidence of misconduct, rather than reinforcing geography as a proxy for data quality. 

Taken together, the two announcements suggest that FDA is thinking about when regulatory friction enters the development process and how to address it earlier. That is encouraging, but neither recent initiative is revolutionary on its own. The Expedited IND Pilot will be useful if it identifies which elements of intensive FDA engagement can be delegated or eliminated rather than simply demonstrating that close attention improves outcomes. Likewise, greater scrutiny of clinical data should remain anchored in alignment with GCP – not drift into a presumption that evidence generated outside the United States is inherently less reliable, as has been implied. The objective should be a regulatory system that is faster because it is clearer and more predictable, not one that depends on extraordinary FDA involvement or crude proxies for risk.